Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of November 30th – December 6th, 2020.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view the full article.
RWB Technical Chart Update: Trend Reversal Confirmed, Major Breakout Imminent?
Considering Red White & Bloom’s (OTCQX:RWBYF) Q3 results included only a couple of weeks worth of Platinum Vape sales and zero PharmaCo revenue, investors and analysts are already salivating over the blockbuster potential of the company’s Q4 Earnings and the smart money is already getting positioned.
Over the Last Decade, the Pot Stock Wave Was One of the Best Opportunities for Investors to Make Money
However, it looks like the next big opportunity could be in Psychedelics. The first big-name investors signalling that Psychedelic Stocks could hold tremendous potential is Shark Tank billionaire investor Kevin O’Leary and Bruce Linton, founder and former CEO of Canopy Growth (NASDAQ:CGC). Both these big-name investors are shareholders in MindMed (OTCQB:MMEDF).
There is a New Pure-Play Cannabidiol (CBD) Company Coming to Market, and the Timing Couldn’t Be Better
Underpinned by a strong cannabis market and favorable regulatory trends, HempFusion Wellness is looking to make its mark. TDR profiles the company sharing peer Big Board listing prowess with Charlottes Web (OTCQX:CWBHF), as well as pertinent details of the initial public offering.
The Psychedelic Space Has Been Heating up With Major Players Debuting on the Public Markets or Raising Significant Capital and With Society Slowly, But Surely, Becoming Accepting of Drug Culture
MindMed (OTCQB:MMEDF) is a biotech Psychedelic medicine company focused on the clinical development of LSD, Ibogaine, MDMA, DMT, and Psilocybin for anxiety, depression, addiction, ADHD, and more.Despite MindMed being up 428.40% (at the time of writing) since its IPO (on NEO) back only on March 3rd, 2020, I believe that it remains a fantastic buy with a massive upside for both short-term and long-term gains and I will lay out my thesis on why investors should consider investing.
Haywood Analyst Neal Gilmer is Giving the Thumbs Up to Aphria’s New SweetWater Acquisition, Which Just Provided the Company Entry Into the U.S. Market
BofA Securities Released a Cannabis Primer That Largely Focused on Canadian Operators, Such as Canopy Growth, as Well as That of the U.S. Cannabis Markets
Bryan D. Spillane, BofA’s research analyst, specifically highlights Canopy Growth (NASDAQ:CGC) on their first page, saying, “Canopy well positioned for additional US market access.” Canopy will have roughly $70 billion in total addressable market by full-year 2023; with the U.S. market contributing $60 billion of that, as per estimates.
Psychedelic Drugs Are Going Mainstream Fast, With Research Supporting Their Effectiveness in Alleviating Emotional Problems
With the recent legalization of Psychedelics in various states, it won’t be long when they line up pharmacy aisles. It is imperative to invest in Psychedelic Stocks that are needle-movers having the most potential for sustained success. Here are three that stand out right now: Champignon Brands (OTCQB:SHRMF), MindMed (OTCQB:MMEDF) and Hollister Biosciences (OTC:HSTRF).
The Mere Possibility of Cannabis Reform in the U.S. Sent This Pot Stock Screaming Higher Last Month
Canadian Licensed Producer (LP) Aurora Cannabis (NYSE:ACB) had a month for the record books in November. The pot company’s stock rose by a whopping 188% over the course of the month, according to data from S&P Global Market Intelligence. The spark? Aurora’s shares took flight for two reasons:
The First-of-its-Kind Trial in Canada Will Pave the Way for Expanded MDMA-Assisted Treatment to Support Patients With PTSD
Numinus Wellness (OTC:LKYSD) and the Multidisciplinary Association for Psychedelic Studies (MAPS) announced a collaboration agreement that will seek approval to deliver MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) through a single-arm, open-label, compassionate access trial.
Publicly Traded MSOs Enjoyed Robust Q3 Financial Performances, Bolstered By Sizzling Sales Growth During the Coronavirus Pandemic and a Focus on State Markets That Are Growing
Moreover, several Multi-State Operators (MSOs) – including Cresco Labs (OTCQX:CRLBF), Green Thumb (OTCQX:GTBIF) and Trulieve (OTCQX:TCNNF) – actually posted profits, expanding an elite club within an industry where many Pot Stocks are bleeding red ink.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.